| 2024 |
Gargett, T., Truong, N. T. H., Gardam, B., Yu, W., Ebert, L. M., Johnson, A., . . . Brown, M. P. (2024). Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. Journal for ImmunoTherapy of Cancer, 12(5), e008659-1-e008659-17. DOI Scopus42 WoS40 Europe PMC31 |
| 2024 |
Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M. N., Pitson, S. M., . . . Brown, M. P. (2024). Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology, 13(7), e1519-1-e1519-20. DOI Scopus12 WoS11 Europe PMC10 |
| 2023 |
Yu, W., Gargett, T., & Du, Z. (2023). A Poisson distribution-based general model of cancer rates and a cancer risk-dependent theory of aging. Aging, 15(17), 8537-8551. DOI Scopus2 WoS3 Europe PMC1 |
| 2022 |
Gargett, T., Ebert, L. M., Truong, N. T. H., Kollis, P. M., Sedivakova, K., Yu, W., . . . Brown, M. P. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 10(9), 1-15. DOI Scopus93 WoS91 Europe PMC89 |
| 2021 |
El Khawanky, N., Hughes, A., Yu, W., Myburgh, R., Matschulla, T., Taromi, S., . . . Zeiser, R. (2021). Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun, 12(1), 6436-1-6436-20. DOI Scopus94 WoS91 Europe PMC89 |
| 2020 |
Ebert, L. M., Yu, W., Gargett, T., Toubia, J., Kollis, P. M., Tea, M. N., . . . Brown, M. P. (2020). Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clinical and Translational Immunology, 9(10), 1-24. DOI Scopus58 WoS56 Europe PMC53 |
| 2020 |
Mekonnen, Z. A., Masavuli, M. G., Yu, W., Gummow, J., Whelan, D. M., Al-Delfi, Z., . . . Grubor-Bauk, B. (2020). Enhanced T cell responses induced by a necrotic dendritic cell vaccine, expressing HCV NS3. Front Microbiol, 11(559105), 1-13. DOI Scopus8 WoS6 Europe PMC7 |
| 2019 |
Gargett, T., TRUONG, N., EBERT, L., YU, W., & BROWN, M. (2019). Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Cytotherapy, 21(6), 593-602. DOI Scopus34 WoS33 Europe PMC37 |
| 2018 |
Wijesundara, D., Gummow, J., Li, Y., Yu, W., Quah, B., Ranasinghe, C., . . . Grubor-Bauk, B. (2018). Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. Journal of Virology, 92(8), 1-15. DOI Scopus22 WoS23 Europe PMC23 |
| 2018 |
Ebert, L. M., Yu, W., Gargett, T., & Brown, M. P. (2018). Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochemical Society Transactions, 46(2), 391-401. DOI Scopus30 WoS29 Europe PMC25 |
| 2017 |
Hughes, A. E., Clarson, J., Gargett, T., Yu, W., Brown, M. P., Lopez, A. F., . . . Yong, A. S. M. (2017). Comment on 'KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study'. Leukemia research, 55, 55-57. DOI Scopus3 WoS3 Europe PMC3 |
| 2017 |
Wijesundara, D., Yu, W., Quah, B., Eldi, P., Hayball, J., Diener, K., . . . Grubor-Bauk, B. (2017). Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner. Scientific Reports, 7(1), 8530-1-8530-8. DOI Scopus8 WoS9 Europe PMC9 |
| 2016 |
Grubor-Bauk, B., Yu, W., Wijesundara, D., Gummow, J., Garrod, T., Brennan, A., . . . Gowans, E. (2016). Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Therapy, 23(1), 26-37. DOI Scopus25 WoS24 Europe PMC25 |
| 2016 |
Gargett, T., Yu, W., Dotti, G., Yvon, E., Christo, S., Hayball, J., . . . Brown, M. (2016). GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Molecular Therapy, 24(6), 1135-1149. DOI Scopus329 WoS304 Europe PMC292 |
| 2015 |
Tomusange, K., Yu, W., Suhrbier, A., Wijesundara, D., Grubor-Bauk, B., & Gowans, E. (2015). Engineering human rhinovirus serotype-A1 as a vaccine vector. Virus Research, 203, 72-76. DOI Scopus7 WoS6 Europe PMC4 |
| 2015 |
Gummow, J., Li, Y., Yu, W., Garrod, T., Wijesundara, D., Brennan, A., . . . Gowans, E. (2015). A multiantigenic DNA vaccine that induces broad hepatitis C virus-specific T-Cell responses in mice. Journal of Virology, 89(15), 7991-8002. DOI Scopus24 WoS26 Europe PMC24 |
| 2014 |
Yu, W., Grubor-Bauk, B., Mullick, R., Das, S., & Gowans, E. J. (2014). Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 10(12), 3576-3578. DOI WoS2 |
| 2014 |
Yu, W., Grubor-Bauk, B., Gargett, T., Garrod, T., & Gowans, E. (2014). A novel challenge model to evaluate the efficacy of hepatitis C virus vaccines in mice. Vaccine, 32(27), 3409-3416. DOI Scopus17 WoS16 Europe PMC12 |
| 2014 |
Garrod, T., Gargett, T., Yu, W., Major, L., Burrell, C., Wesselingh, S., . . . Gowans, E. (2014). Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. Virus Research, 192, 25-33. DOI Scopus6 WoS6 Europe PMC7 |
| 2014 |
Garrod, T., Grubor-Bauk, B., Gargett, T., Li, Y., Miller, D., Yu, W., . . . Gowans, E. (2014). DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency. European Journal of Immunology, 44(7), 1992-2002. DOI Scopus24 WoS21 Europe PMC19 |
| 2014 |
Garrod, T., Grubor-Bauk, B., Yu, S., Gargett, T., & Gowans, E. (2014). Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency. Human Vaccines and Immunotherapeutics, 10(9), 2679-2683. DOI Scopus10 WoS11 Europe PMC9 |
| 2014 |
Gargett, T., Grubor-Bauk, B., Garrod, T., Yu, W., Miller, D., Major, L., . . . Gowans, E. (2014). Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. Immunology and Cell Biology, 92(4), 359-367. DOI Scopus24 WoS25 Europe PMC25 |
| 2014 |
Gargett, T., Grubor-Bauk, B., Miller, D., Garrod, T., Yu, S., Wesselingh, S., . . . Gowans, E. (2014). Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein. Clinical and Translational Immunology, 3(6), e18-1-e18-7. DOI Scopus24 WoS21 Europe PMC20 |
| 2014 |
Yu, W., Grubor-Bauk, B., Mullick, R., Das, S., & Gowans, E. J. (2014). Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines. Human vaccines & immunotherapeutics, 10(12), 3576-3578. DOI Scopus3 Europe PMC3 |
| 2013 |
Zhou, J., Cheung, A. K. L., Tan, Z., Wang, H., Yu, W., Du, Y., . . . Chen, Z. (2013). PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8(+) T cells in mice. Journal of clinical investigation, 123(6), 2629-2642. DOI Scopus65 Europe PMC53 |
| 2013 |
Xiao, H., Liu, L., Zhu, Q., Tan, Z., Yu, W., Tang, X., . . . Chen, Z. (2013). A replicating modified Vaccinia Tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. PLoS One, 8(12, article no. e83273), 1-10. DOI Scopus10 Europe PMC8 |
| 2011 |
Yu, W. B., Liu, L., & Chen, Z. W. (2011). Attenuation of the smallpox vaccine Vaccinia Tiantan strain and its use as a safe vaccine live vector. Chinese journal of viral diseases, 1(1), 75-80. |
| 2011 |
Lu, B., Yu, W., Huang, X., Wang, H., Liu, L., & Chen, Z. (2011). Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: Vaccinia Tiantan strain. Journal of biomedicine and biotechnology, 2011(970424), 1-9. DOI |
| 2010 |
Liu, H., Yu, W., Tang, X., Wang, H., Ouyang, W., Zhou, J., & Chen, Z. (2010). The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice. Journal of medical virology, 82(5), 727-734. DOI Scopus13 Europe PMC13 |
| 2009 |
Huang, X., Lu, B., Yu, W., Fang, Q., Liu, L., Zhuang, K., . . . Chen, Z. (2009). A novel replication-competent vaccinia vector MVTT Is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One, 4(1, article no. e4180), 1-9. DOI Scopus45 Europe PMC39 |
| 2009 |
Yu, W., Fang, Q., Zhu, W., Wang, H., Tien, P., Zhang, L., & Chen, Z. (2009). One time intranasal vaccination with a modified vaccinia Tiantan strain MVTTZCI protects animals against pathogenic viral challenge. Vaccine, 28(9), 2088-2096. DOI Scopus22 Europe PMC19 |
| 2007 |
Zhu, W., Fang, Q., Zhuang, K., Wang, H., Yu, W., Zhou, J., . . . Chen, Z. (2007). The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. Journal of Virological Methods, 144(1-2), 17-26. DOI Scopus32 Europe PMC26 |
| 2005 |
Fang, Q., Yang, L., Zhu, W., Liu, L., Wang, H., Yu, W., . . . Chen, Z. (2005). Host range, growth property, and virulence of the smallpox vaccine: Vaccinia virus Tian Tan strain. Virology, 335(2), 242-251. DOI Scopus58 Europe PMC53 |
Available For Media Comment.